{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T13:57:41Z","timestamp":1790863061474,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T00:00:00Z","timestamp":1724716800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T00:00:00Z","timestamp":1724716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100015539","name":"Australian Government","doi-asserted-by":"publisher","award":["Australian Government Research Training Program"],"award-info":[{"award-number":["Australian Government Research Training Program"]}],"id":[{"id":"10.13039\/100015539","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001774","name":"University of Sydney","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001774","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Enoxaparin is dosed according to actual body weight in treatment of arterial and venous thrombosis. Due to its hydrophilic nature, it distributes according to lean body mass which may be problematic when dosing obese patients as this may increase the risk of bleeding events in this population. The aim\u00a0was\u00a0to evaluate current therapeutic enoxaparin dosing strategies, including Antifactor Xa (AFXa) level monitoring, in obese patients and to identify factors that contribute to treatment failure and excess anticoagulation. A retrospective cohort study was conducted reviewing patients administered therapeutic enoxaparin between May 2020 and April 2021. Data were collected on patient characteristics, enoxaparin therapy, AFXa monitoring, and outcomes. Regression models were constructed to assess variables of interest to estimate any association with AFXa levels. In total 762 patients were included in the analysis. The mean initial weight-based dose was 0.95\u00a0mg\/kg twice daily (SD:\u2009\u00b1\u20090.12, IQR 0.92\u20131.01) and 1.04\u00a0mg\/kg once daily (SD:\u2009\u00b1\u20090.26, IQR 0.93\u20131.12) and 14.4% of patients had AFXa monitoring. Treatment failure was experienced by 2.2%, 5% experienced bleeding. There was no association between the mean actual milligram per kilogram weight-based twice daily doses and subtherapeutic, therapeutic and supratherapeutic AFXa levels\u00a0(P\u2009=\u20090.135). Obesity was not included\u00a0in the final regression models due to lack of significance. At a mean therapeutic enoxaparin dose of 0.95\u00a0mg\/kg twice daily and 1.04\u00a0mg\/kg once daily no excess in treatment failure or bleeding events were observed in obese patients compared to the product information. Obesity was not an independent variable that affected the achievement of target AFXa levels.<\/jats:p>\n          <jats:p>\n            <jats:bold>Graphical abstract<\/jats:bold>\n          <\/jats:p>","DOI":"10.1007\/s11239-024-03033-7","type":"journal-article","created":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T09:03:04Z","timestamp":1724749384000},"page":"109-119","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Finding individualised treatment in obese needing enoxaparin (FIT ONE): a multicentre study of therapeutic enoxaparin and the role of anti-factor Xa monitoring"],"prefix":"10.1007","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-6910-697X","authenticated-orcid":false,"given":"Marcelle","family":"Appay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine","family":"Hay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connie","family":"Calvisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"Wills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shreyas","family":"Kharadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajani","family":"Nanayakkara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Sang","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rozanna","family":"Alameddine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Jupp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaretta","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tammy","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fady","family":"Gad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakura","family":"Kagaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liam","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharma","family":"Piyush","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicky","family":"Shion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Advait","family":"Pandya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Emin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewe Shen","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urna","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Hayat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chamali","family":"Gajaweera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nashwa","family":"Sheriff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asad E.","family":"Patanwala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Pasalic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan-Willem","family":"Alffenaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,27]]},"reference":[{"key":"3033_CR1","unstructured":"MIMs (2023) Clexane and Clexane Forte 2023. https:\/\/www.mimsonline.com.au.acs.hcn.com.au\/Search\/FullPI.aspx?ModuleName=Product%20Info&searchKeyword=enoxaparin&PreviousPage=~\/Search\/QuickSearch.aspx&SearchType=&ID=26580003_2. Accessed 01 Jan 2024"},{"issue":"3","key":"3033_CR2","doi-asserted-by":"publisher","first-page":"215","DOI":"10.2165\/00003088-200039030-00004","volume":"39","author":"G Cheymol","year":"2000","unstructured":"Cheymol G (2000) Effects of obesity on pharmacokinetics: implications for drug therapy. Clin Pharmacokinet 39(3):215\u2013231","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"3033_CR3","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1146\/annurev-pharmtox-010814-124354","volume":"55","author":"CAJ Knibbe","year":"2015","unstructured":"Knibbe CAJ, Brill MJE, van Rongen A, Diepstraten J, van der Graaf PH, Danhof M (2015) Drug disposition in obesity: toward evidence-based dosing. Annu Rev Pharmacol Toxicol 55(1):149\u2013167","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"5","key":"3033_CR4","doi-asserted-by":"publisher","first-page":"277","DOI":"10.2165\/11599410-000000000-00000","volume":"51","author":"MJE Brill","year":"2012","unstructured":"Brill MJE, Diepstraten J, van Rongen A, van Kralingen S, van den Anker JN, Knibbe CAJ (2012) Impact of obesity on drug metabolism and elimination in adults and children. Clin Pharmacokinet 51(5):277\u2013304","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"3033_CR5","doi-asserted-by":"publisher","first-page":"e224","DOI":"10.1097\/MJT.0000000000000401","volume":"25","author":"NR Srinivas","year":"2018","unstructured":"Srinivas NR (2018) Influence of morbid obesity on the clinical pharmacokinetics of various anti-infective drugs: reappraisal using recent case studies-issues, dosing implications, and considerations. Am J Ther 25(2):e224\u2013e246","journal-title":"Am J Ther"},{"issue":"6","key":"3033_CR6","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1177\/1076029614568713","volume":"21","author":"NR Thompson-Moore","year":"2015","unstructured":"Thompson-Moore NR, Wanat MA, Putney DR, Liebl PHN, Chandler WL, Muntz JE (2015) Evaluation and pharmacokinetics of treatment dose enoxaparin in hospitalized patients with morbid obesity. Clin Appl Thromb Hemost 21(6):513\u2013520","journal-title":"Clin Appl Thromb Hemost"},{"key":"3033_CR7","unstructured":"World Health Organisation (WHO) (2021) Obesity and overweight 2021. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight. Accessed 01 Jan 2024"},{"key":"3033_CR8","doi-asserted-by":"crossref","unstructured":"Australian Institute of Health and Welfare (2023) Overweight and obesity: Australian government. https:\/\/www.aihw.gov.au\/reports\/overweight-obesity\/overweight-and-obesity\/contents\/overweight-and-obesity. Accessed 19 May 2023","DOI":"10.1093\/hesc\/9780198866671.003.0021"},{"issue":"5","key":"3033_CR9","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1097\/MOH.0b013e3283634443","volume":"20","author":"IO Blokhin","year":"2013","unstructured":"Blokhin IO, Lentz SR (2013) Mechanisms of thrombosis in obesity. Curr Opin Hematol 20(5):437\u2013444","journal-title":"Curr Opin Hematol"},{"issue":"6","key":"3033_CR10","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1592\/phco.29.6.631","volume":"29","author":"SA Spinler","year":"2009","unstructured":"Spinler SA, Ou FS, Roe MT, Gibler WB, Ohman EM, Pollack CV et al (2009) Weight-based dosing of enoxaparin in obese patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE initiative. Pharmacotherapy 29(6):631\u2013638","journal-title":"Pharmacotherapy"},{"issue":"6","key":"3033_CR11","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1345\/aph.1L194","volume":"43","author":"EA Nutescu","year":"2009","unstructured":"Nutescu EA, Spinler SA, Wittkowsky A, Dager WE (2009) Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings. Ann Pharmacother 43(6):1064\u20131083","journal-title":"Ann Pharmacother"},{"issue":"4","key":"3033_CR12","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1111\/j.1538-7933.2004.00647.x","volume":"2","author":"J Harenberg","year":"2004","unstructured":"Harenberg J (2004) Is laboratory monitoring of low-molecular-weight heparin therapy necessary? J Thromb Haemost 2(4):547\u2013550","journal-title":"J Thromb Haemost"},{"issue":"5","key":"3033_CR13","doi-asserted-by":"publisher","first-page":"227","DOI":"10.5694\/mja2.50004","volume":"210","author":"HA Tran","year":"2019","unstructured":"Tran HA, Gibbs H, Merriman E, Curnow JL, Young L, Bennett A et al (2019) New guidelines from the thrombosis and haemostasis society of Australia and New Zealand for the diagnosis and management of venous thromboembolism. Med J Aust 210(5):227\u2013235","journal-title":"Med J Aust"},{"issue":"1","key":"3033_CR14","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ejvs.2020.09.023","volume":"61","author":"SK Kakkos","year":"2021","unstructured":"Kakkos SK, Gohel M, Baekgaard N, Bauersachs R, Bellmunt-Montoya S, Black SA et al (2021) European Society for Vascular Surgery (ESVS) 2021 clinical practice guidelines on the management of venous thrombosis. Eur J Vasc Endovasc Surg 61(1):9","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"19","key":"3033_CR15","doi-asserted-by":"publisher","first-page":"4693","DOI":"10.1182\/bloodadvances.2020001830","volume":"4","author":"TL Ortel","year":"2020","unstructured":"Ortel TL, Neumann I, Ageno W, Beyth R, Clark NP, Cuker A et al (2020) American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv 4(19):4693\u20134738","journal-title":"Blood Adv"},{"issue":"22","key":"3033_CR16","doi-asserted-by":"publisher","first-page":"3257","DOI":"10.1182\/bloodadvances.2018024893","volume":"2","author":"DM Witt","year":"2018","unstructured":"Witt DM, Nieuwlaat R, Clark NP, Ansell J, Holbrook A, Skov J et al (2018) American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. Blood Adv 2(22):3257\u20133291","journal-title":"Blood Adv"},{"key":"3033_CR17","doi-asserted-by":"publisher","DOI":"10.1177\/10600280241256351","author":"M Appay","year":"2024","unstructured":"Appay M, Kharadi S, Nanayakkara S, Ryu JS, Pasalic L, Alffenaar JW (2024) Therapeutic enoxaparin dosing in obesity. Ann Pharmacother. https:\/\/doi.org\/10.1177\/10600280241256351","journal-title":"Ann Pharmacother"},{"key":"3033_CR18","unstructured":"Australian Institute of Health and Welfare (2015) Australian hospital peer groups 2015. https:\/\/www.aihw.gov.au\/reports\/hospitals\/australian-hospital-peer-groups\/data. Accessed 01 Feb 2024"},{"key":"3033_CR19","unstructured":"NSW Health Pathology (2024) NSW health pathology test catalogue: anti factor Xa 2024. https:\/\/catalogue.pathology.health.nsw.gov.au\/search?searchValue=Anti%20factor%20Xa&searchType=startsWith&page=1&pageSize=10"},{"issue":"6","key":"3033_CR20","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1055\/s-0032-1319768","volume":"38","author":"DM Adcock Funk","year":"2012","unstructured":"Adcock Funk DM, Lippi G, Favaloro EJ (2012) Quality standards for sample processing, transportation, and storage in hemostasis testing. Semin Thromb Hemost 38(6):576\u2013585","journal-title":"Semin Thromb Hemost"},{"key":"3033_CR21","unstructured":"Centers for Disease Control and Prevention (CDC) (2022) Overweight and obesity 2022. https:\/\/www.cdc.gov\/obesity\/basics\/adult-defining.html. Accessed 06 Feb 2024"},{"issue":"4","key":"3033_CR22","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"S Schulman","year":"2005","unstructured":"Schulman S, Kearon C (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3(4):692\u2013694","journal-title":"J Thromb Haemost"},{"issue":"11","key":"3033_CR23","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1111\/jth.13140","volume":"13","author":"S Kaatz","year":"2015","unstructured":"Kaatz S, Ahmad D, Spyropoulos AC, Schulman S (2015) Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost 13(11):2119\u20132126","journal-title":"J Thromb Haemost"},{"issue":"19","key":"3033_CR24","doi-asserted-by":"publisher","first-page":"4929","DOI":"10.1182\/bloodadvances.2020002482","volume":"4","author":"AJ Darzi","year":"2020","unstructured":"Darzi AJ, Repp AB, Spencer FA, Morsi RZ, Charide R, Etxeandia-Ikobaltzeta I et al (2020) Risk-assessment models for VTE and bleeding in hospitalized medical patients: an overview of systematic reviews. Blood Adv 4(19):4929\u20134944","journal-title":"Blood Adv"},{"key":"3033_CR25","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.007901","author":"JD Brown","year":"2018","unstructured":"Brown JD, Goodin AJ, Lip GYH, Adams VR (2018) Risk stratification for bleeding complications in patients with venous thromboembolism: application of the HAS-BLED bleeding score during the first 6 months of anticoagulant treatment. J Am Heart Assoc. https:\/\/doi.org\/10.1161\/JAHA.117.007901","journal-title":"J Am Heart Assoc"},{"issue":"12","key":"3033_CR26","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1177\/1060028013506404","volume":"47","author":"JC Hagopian","year":"2013","unstructured":"Hagopian JC, Riney JN, Hollands JM, Deal EN (2013) Assessment of bleeding events associated with short-duration therapeutic enoxaparin use in the morbidly obese. Ann Pharmacother 47(12):1641\u20131648","journal-title":"Ann Pharmacother"},{"issue":"1","key":"3033_CR27","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1177\/08971900211022300","volume":"36","author":"O Berger","year":"2023","unstructured":"Berger O, Sebaaly J, Crawford R, Rector K, Anderson W (2023) Evaluation of a treatment-dose enoxaparin protocol for patients with obesity. J Pharm Pract 36(1):74\u201378","journal-title":"J Pharm Pract"},{"issue":"1","key":"3033_CR28","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s40261-019-00855-9","volume":"40","author":"YR Lee","year":"2020","unstructured":"Lee YR, Palmere PJ, Burton CE, Benavides TM (2020) Stratifying therapeutic enoxaparin dose in morbidly obese patients by BMI class: a retrospective cohort study. Clin Drug Investig 40(1):33\u201340","journal-title":"Clin Drug Investig"},{"issue":"4","key":"3033_CR29","first-page":"3084","volume":"20","author":"J Niu","year":"2020","unstructured":"Niu J, Song Y, Li C, Ren H, Zhang W (2020) Once-daily vs. twice-daily dosing of enoxaparin for the management of venous thromboembolism: a systematic review and meta-analysis. Exp Ther Med 20(4):3084\u20133095","journal-title":"Exp Ther Med"},{"issue":"9","key":"3033_CR30","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.hlc.2016.06.789","volume":"25","author":"DPMMPHF Chew","year":"2016","unstructured":"Chew DP, Scott IA, Cullen L, French JK, Briffa TG, Tideman PA et al (2016) National Heart Foundation of Australia & Cardiac Society of Australia and New Zealand: Australian Clinical Guidelines for the Management of Acute Coronary Syndromes 2016. Heart Lung Circ 25(9):895\u2013951","journal-title":"Heart Lung Circ"},{"issue":"2","key":"3033_CR31","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1007\/s11239-011-0584-7","volume":"32","author":"EN Deal","year":"2011","unstructured":"Deal EN, Hollands JM, Riney JN, Skrupky LP, Smith JR, Reichley RM (2011) Evaluation of therapeutic anticoagulation with enoxaparin and associated anti-Xa monitoring in patients with morbid obesity: a case series. J Thromb Thrombolysis 32(2):188\u2013194","journal-title":"J Thromb Thrombolysis"},{"key":"3033_CR32","first-page":"63","volume":"10","author":"L Tahaineh","year":"2018","unstructured":"Tahaineh L, Edaily SM, Gharaibeh SF (2018) Anti-factor Xa levels in obese patients receiving enoxaparin for treatment and prophylaxis indications. Clin Pharmacol: Adv Appl 10:63\u201370","journal-title":"Clin Pharmacol: Adv Appl"},{"issue":"6","key":"3033_CR33","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1177\/1060028018821149","volume":"53","author":"MA Curry","year":"2019","unstructured":"Curry MA, LaFollette JA, Alexander BR, Evans KS, Tran RH, Kempton CL (2019) Evaluation of treatment-dose enoxaparin in acutely Ill morbidly obese patients at an academic medical center: a randomized clinical trial. Ann Pharmacother 53(6):567\u2013573","journal-title":"Ann Pharmacother"},{"issue":"1","key":"3033_CR34","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.thromres.2004.10.004","volume":"116","author":"A Bazinet","year":"2005","unstructured":"Bazinet A, Almanric K, Brunet C, Turcotte I, Martineau J, Caron S et al (2005) Dosage of enoxaparin among obese and renal impairment patients. Thromb Res 116(1):41\u201350","journal-title":"Thromb Res"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-024-03033-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-024-03033-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-024-03033-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T18:24:53Z","timestamp":1737829493000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-024-03033-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,27]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["3033"],"URL":"https:\/\/doi.org\/10.1007\/s11239-024-03033-7","relation":{},"ISSN":["1573-742X"],"issn-type":[{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,27]]},"assertion":[{"value":"11 August 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}